Abstract 3099: Selective CDK2 inhibition with ECI830: preclinical characterization, efficacy, and on-target mechanism supported by biomarker and gene signature analysisOphélia Maertens, Samuel B. Ho, Bradley French et al.|Cancer Research|2026Cited by 0
Abstract ND06: ECI830, a potent and highly selective CDK2 inhibitor, for the treatment of HR+/HER2− breast cancer and <i>CCNE1</i> -amplified tumorsSamuel Ho, Vivek Rauniyar, Imad Hanna et al.|Cancer Research|2026Cited by 0